Bin Xian Wei
Directeur/Membre du Conseil chez PALISADE BIO, INC.
Fortune : 12 $ au 30/04/2024
Postes actifs de Bin Xian Wei
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PALISADE BIO, INC. | Directeur/Membre du Conseil | 01/01/2019 | - |
| Independent Dir/Board Member | - | - | |
| Dar Sheng Trade & Technic Development Co. Ltd. | Corporate Officer/Principal | 01/01/2015 | - |
Historique de carrière de Bin Xian Wei
Anciens postes connus de Bin Xian Wei
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SAKAI TRADING CO., LTD. | Corporate Officer/Principal | 01/01/2008 | 01/01/2010 |
| PALISADE BIO, INC. | Directeur/Membre du Conseil | 05/02/2019 | - |
| Independent Dir/Board Member | 05/02/2019 | - |
Formation de Bin Xian Wei
| Tianjin University | Undergraduate Degree |
| Colorado School of Mines | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
| Chine | 3 |
| Japon | 2 |
Opérationnelle
| Director/Board Member | 2 |
| Independent Dir/Board Member | 2 |
| Corporate Officer/Principal | 2 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
| Distribution Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PALISADE BIO, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Sakai Trading Co., Ltd.
 Sakai Trading Co., Ltd. Wholesale DistributorsDistribution Services Sakai Trading Co., Ltd. engages in imports and exports chemical, synthetic resins and electronic materials. It operates through the Domestic and Overseas segments. The Domestic segment manages the domestic operations of the company's products. The Overseas segment handles the overseas operations through its subsidiaries located overseas. The company was founded February 10, 1936 and is headquartered in Osaka, Japan. | Distribution Services |
Seneca Biopharma, Inc.
 Seneca Biopharma, Inc. BiotechnologyHealth Technology Seneca Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD. | Health Technology |
| Dar Sheng Trade & Technic Development Co. Ltd. |
- Bourse
- Insiders
- Bin Xian Wei
- Expérience
